Inhibrx Biosciences, Inc. INBX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Inhibrx Biosciences, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s return on equity?
- Inhibrx Biosciences, Inc. (INBX) reported return on equity of -197.8% in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s return on equity changed year-over-year?
- Inhibrx Biosciences, Inc.'s return on equity decreased by 110.1% year-over-year, from 1,960% to -197.8%.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s return on equity?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s return on equity has grown at a -35.5% compound annual growth rate (CAGR), from -475.3% to -197.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.